Literature DB >> 2310313

Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination.

W W Beatty1, D E Goodkin.   

Abstract

The usefulness of the Mini-Mental State Examination (MMSE) as a screening test for identifying cognitive impairment in patients with multiple sclerosis (MS) has been questioned because many patients who score above the suggested cutoff score of 24 exhibit severe focal or global cognitive deficits. We reevaluated the usefulness of the MMSE by studying 85 patients with clinically definite MS who also received an extensive battery of neuropsychological tests. Although scores on the MMSE were negatively correlated with the number of neuropsychological tests on which patients with MS displayed impairment, the MMSE was not sufficiently sensitive to identify precisely defined dementia in these patients. The MMSE was nonetheless a useful predictor of focal cognitive impairment, particularly in relapsing-remitting patients with relatively minor physical disabilities. Additional analyses suggested strategies for minor modifications of the MMSE that may improve its sensitivity and specificity for identifying dementia while preserving its major advantages as a screening examination: brevity and ease of administration and scoring.

Entities:  

Mesh:

Year:  1990        PMID: 2310313     DOI: 10.1001/archneur.1990.00530030069018

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  22 in total

1.  Multiple sclerosis and the mind.

Authors:  M A Ron; A Feinstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

Review 2.  Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.

Authors:  Alexander Rae-Grant; Amy Bennett; Amy E Sanders; Michael Phipps; Eric Cheng; Christopher Bever
Journal:  Neurology       Date:  2015-09-02       Impact factor: 9.910

Review 3.  Cognitive screening in multiple sclerosis.

Authors:  Peter Scherer
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

4.  Psychophysiological and electrophysiological testing of olfactory and gustatory function in patients with multiple sclerosis.

Authors:  Sarah Bettina Dahlslett; Oender Goektas; Felix Schmidt; Lutz Harms; Heidi Olze; Franca Fleiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-06       Impact factor: 2.503

5.  Measuring outcomes in acute neurorehabilitation in General Hospital setting - our experience.

Authors:  Emela Mujić-Skikić; Suad Trebinjac; Dijana Avdić; Amra Dzumhur-Sarić
Journal:  Bosn J Basic Med Sci       Date:  2006-08       Impact factor: 3.363

6.  High concurrent presence of disability in multiple sclerosis. Associations with perceived health.

Authors:  Sverker Johansson; Charlotte Ytterberg; Ingrid M Claesson; Jenny Lindberg; Jan Hillert; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

7.  Evaluation of retinal and choroidal changes in patients with Alzheimer's type dementia using optical coherence tomography angiography.

Authors:  Ze-Bing Li; Zhong-Jing Lin; Na Li; Huan Yu; Yan-Lin Wu; Xi Shen
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

8.  Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers.

Authors:  Marta Bassi; Monica Falautano; Sabina Cilia; Benedetta Goretti; Monica Grobberio; Marianna Pattini; Erika Pietrolongo; Rosa Gemma Viterbo; Maria Pia Amato; Miriam Benin; Alessandra Lugaresi; Eleonora Minacapelli; Enrico Montanari; Francesco Patti; Maria Trojano; Antonella Delle Fave
Journal:  J Clin Psychol Med Settings       Date:  2016-03

9.  [On the value of neuropsychological short tests in epileptology].

Authors:  J Rösche; C Uhlmann; W Fröscher
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

Review 10.  Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

Authors:  Bridget Bagert; Patricia Camplair; Dennis Bourdette
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.